Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study

OBJECTIVE: To report the 5‐year efficacy and safety of secukinumab in the treatment of patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT01392326). METHODS: Following the 2‐year core trial, eligible patients receiving subcutaneous secukinumab entered a 3‐year extension phase. Results...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J., Kavanaugh, Arthur, Reimold, Andreas, Tahir, Hasan, Rech, Juergen, Hall, Stephen, Geusens, Piet, Pellet, Pascale, Delicha, Eumorphia Maria, Pricop, Luminita, Mpofu, Shephard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957920/
https://www.ncbi.nlm.nih.gov/pubmed/31943974
http://dx.doi.org/10.1002/acr2.11097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957920/
https://www.ncbi.nlm.nih.gov/pubmed/31943974
http://dx.doi.org/10.1002/acr2.11097

Ejemplares similares